Several respiratory and autoimmune diseases may be caused, at least in part, by a lack of sufficient native CC10 protein in patients. We are developing a pharmaceutical therapy to replace CC10 with the synthetic version (rhCC10) in respiratory diseases characterized by inflammation and pre-existing CC10 deficiency.
Secretoglobins are naturally occurring proteins produced in the body by Club Cells. They are some of the most abundant proteins secreted in the airways. Naturally occurring CC10 is the most abundant protein in the fluid that lines the respiratory tract in both the upper and lower lung, including the sinus cavities. rhCC10 has the potential to modify, or to help resolve inflamed airways in a wide range of respiratory conditions such as asthma, sinusitis, COPD and pulmonary fibrosis, unlike many treatments that provide symptomatic treatment only. Therabron has completed two Phase 1b clinical trials with rhCC10 and is currently enrolling a Phase 2 study in premature infants, who are known to lack sufficient native CC10 in their immature lungs. We are developing a platform of pharmaceutical therapies to replace native CC10 with rhCC10 in an effort to potentially benefit a range of respiratory conditions characterized by inflammation and CC10 deficiency.